Ignite Creation Date:
2025-12-24 @ 12:36 PM
Ignite Modification Date:
2025-12-30 @ 5:23 AM
Study NCT ID:
NCT05911061
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-25
First Post:
2023-06-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
Sponsor:
WestVac Biopharma Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-06-19
First Submit QC Date:
None
Study First Post Date:
2023-06-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-23
Last Update Post Date:
2024-07-25
Last Update Post Date Type:
ACTUAL